Despite Aggressive Pricing, Illumina Expects Outsourced Sequencing to Remain Small Part of Business
June 21, 2011
Despite Aggressive Pricing, Illumina Expects Outsourced Sequencing to Remain Small Part of Business
An Illumina official said that sequencing services will remain a small part of its overall business and that the company does not expect the offering to have a negative impact on its instrument and consumables sales "in any reasonable horizon you could think of."
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Complete Genomics Targets Larger Share of Services Market; Analysts Predict 21K Genomes in 2012
June 7, 2011 / In Sequence - Erasmus Orders 250 Genomes from Complete Genomics to Study Cancer, Congenital Malformations
May 24, 2011 / Clinical Sequencing News - Complete Genomics to Design New Generation of Sequencers; Reports Backlog of 2,100 Genomes
May 10, 2011 / In Sequence - Paired Ends
October 5, 2010 / In Sequence - Illumina Says 'Significant Growth' in Sequencing Demand Drove 12-Percent Rise in Q4 Revenue
February 9, 2010 / In Sequence